跳至主要内容
临床试验/IRCT20230722058883N2
IRCT20230722058883N2已完成3 期

Prognostic Efficacy of Moderate Intensity rosuvastatin on the Infected cases with SARS-Cov-2

Tehran University of Medical Sciences0 个研究点目标入组 100 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
30 years 至 70 years(—)
性别
All

入选标准

  • patients who were not currently taking statin treatment
  • patients who had a confirmed diagnosis of COVID-19 based on imaging or PCR results.

排除标准

  • patients with known liver disease, cirrhosis, autoimmune hepatitis, chronic viral hepatitis, rhabdomyolysis myopathy, severe kidney disease, a history of statin sensitivity, and higher-than-normal ALT and CPK in the initial test.
  • Patients who had previously taken statins at different dosages as well as women who were pregnant or nursing
  • If the patient developed symptoms of hepatitis or myopathy, muscle weakness and increased liver and muscle enzymes after taking statin

研究者

相似试验